Immunovant, a Roivant Sciences company, released positive results from its Phase III study of batoclimab in myasthenia gravis (MG) and initial results from its Phase IIb study in chronic inflammatory demyelinating polyneuropathy (CIDP). The studies showed that deeper IgG reduction leads to deeper responses in patients.
According to Dr. Pete Salzmann, chief executive of Immunovant, the company’s core thesis – that deeper IgG reduction leads to improved clinical outcomes – is expected to apply to a wide range of auto-antibody mediated conditions. However, investors initially reacted negatively to the news, with Immunovant’s stock declining 10% before recovering in early trading.
Source: https://www.thepharmaletter.com/positive-batoclimab-data-from-immunovant-but-doubts-raised-on-further-development